SWE
Toggle navigation
English
Svenska
About Us
The Company
Board & Management
Scientific Advisory Board
Scientific Publications
Events & Mediawatch
Careers
Contact Us
Expanded Access Policy
Diabetes
Products
Manufacturing
Clinical Trials
Investors
Investor Relations
CEO Comments
Corporate Governance
Press Releases
Financial Reports
Financial Calendar
Rights Issue
Skip Navigation Links
Home
»
The Company
»
Scientific Publications
Scientific Publications
Scientific publications related to Diamyd Medicals research and development.
Redosing with Intralymphatic GAD-Alum in the Treatment of Type 1 Diabetes: The DIAGNODE-B Pilot Trial
International Journal of Molecular Sciences, 2025, 26(1), 374
A 1-year pilot study of intralymphatic injections of GAD-alum in individuals with latent autoimmune diabetes in adults (LADA) with signs of high immunity: No safety concerns and resemblance to juvenile Type 1 Diabetes
Diabetes Obes Metab. 2023 Aug 14; 25(11):3400-3409
Phase III, randomised, double-blind, placebo-controlled, multicentre trial to evaluate the efficacy and safety of rhGAD65 to preserve endogenous beta cell function in adolescents and adults with recently diagnosed Type 1 Diabetes, carrying the genetic HLA DR3-DQ2 haplotype: the DIAGNODE-3 study protocol
BMJ Open. 2022 Oct 31;12(10):e061776
Intralymphatic GAD-Alum (Diamyd
®
) Improves Glycemic Control in Type 1 Diabetes With HLA DR3-DQ2
J Clin Endocrinol Metab. 2022 Aug 18;107(9):2644-2651
Association between treatment effect on C-peptide preservation and HbA1c in meta-analysis of glutamic acid decarboxylase (GAD)-alum immunotherapy in recent-onset Type 1 Diabetes
Diabetes Obes Metab. 2022 April 17;24(8):1647-1655.
Intra-lymphatic administration of GAD-alum in Type 1 Diabetes: long-term follow-up and effect of a late booster dose (the DIAGNODE Extension trial)
Acta Diabetol. 2022 Jan 31; 59(5): 687–696
Intralymphatic Glutamic Acid Decarboxylase With Vitamin D Supplementation in Recent-Onset Type 1 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Phase IIb Trial
Diabetes Care. 2021 Jul;44(7):1604-1612.
More on Intralymphatic Injection of Autoantigen in Type 1 Diabetes
N Engl J Med. 2017 Jul 27;377(4):403
Intralymphatic Injection of Autoantigen in Type 1 Diabetes
N Engl J Med. 2017 Feb 16;376(7):697-699
GAD vaccine reduces insulin loss in recently diagnosed Type 1 Diabetes: findings from a Bayesian meta-analysis
Diabetologia. 2017 Jan;60(1):43-49
Order GAD for preclinical research
ORDER
©
Privacy Policy
|
Cookie Policy
|
Expanded Access Policy
Share This Page
select
Facebook
Twitter
LinkedIn
Google Plus
Pinterest
Tumblr
StumbleUpon
Blogger
MySpace
Digg
Reddit
Email
GAD PRODUCTS
Order GAD for preclinical research